Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...

The common forms of type 2 diabetes are caused by a constellation of genetic and epigenetic factors and molecular changes related to diet; lifestyle, including lack of exercise and sleep; ...